The FDA Is Struggling To Police The Peptide Boom
In a commentary first published by Forbes and carried on Yahoo, health expert Sally Pipes argues the FDA's August warning letters to online sellers of unapproved peptides, including the experimental weight-loss drug retatrutide, are a start but miss overseas supply chains. She cites an import-record analysis finding at least eight retatrutide shipments from Chinese manufacturers in the first quarter of 2026, and proposes closer FDA-customs coordination.
Why it matters: Relevant to Maryland adults considering medical weight loss and to clinicians fielding patient questions about peptides sold online outside FDA-approved channels.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to yahoo.com. October 9, 2026.
